Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53

被引：0
|
作者：
Phong Lu
Erica R. Vander Mause
Katherine E. Redd Bowman
Sarah M. Brown
Lisa Ahne
Carol S. Lim
机构：
[1] University of Utah,Department of Pharmaceutics and Pharmaceutical Chemistry
[2] Philipps-Universitat Marburg,undefined
来源：
Journal of Ovarian Research | / 12卷
关键词：
p53; BakMTS; BaxMTS; DBD; Dominant negative; Apoptosis; Mitochondria; Ovarian cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53
    Lu, Phong
    Vander Mause, Erica R.
    Bowman, Katherine E. Redd
    Brown, Sarah M.
    Ahne, Lisa
    Lim, Carol S.
    JOURNAL OF OVARIAN RESEARCH, 2019, 12 (1)
  • [2] Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo
    G Palacios
    U M Moll
    Oncogene, 2006, 25 : 6133 - 6139
  • [3] Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo
    Palacios, G.
    Moll, U. M.
    ONCOGENE, 2006, 25 (45) : 6133 - 6139
  • [4] Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovarian carcinomas
    Wu, Jianyuan
    Li, Qingdi Quentin
    Zhou, Huiping
    Lu, Yinying
    Li, Jueli M.
    Ma, Yao
    Wang, Li
    Fu, Tingting
    Gong, Xingjiang
    Weintraub, Michael
    Wu, Shuangchan
    Ding, Hong
    MEDICAL ONCOLOGY, 2014, 31 (07)
  • [5] Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovarian carcinomas
    Jianyuan Wu
    Qingdi Quentin Li
    Huiping Zhou
    Yinying Lu
    Jueli M. Li
    Yao Ma
    Li Wang
    Tingting Fu
    Xingjiang Gong
    Michael Weintraub
    Shuangchan Wu
    Hong Ding
    Medical Oncology, 2014, 31
  • [6] A Chimeric p53 Evades Mutant p53 Transdominant Inhibition in Cancer Cells
    Okal, Abood
    Mossalam, Mohanad
    Matissek, Karina J.
    Dixon, Andrew S.
    Moos, Philip J.
    Lim, Carol S.
    MOLECULAR PHARMACEUTICS, 2013, 10 (10) : 3922 - 3933
  • [7] Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation
    De Smet, Frederik
    Rubio, Mirian Saiz
    Hompes, Daphne
    Naus, Evelyne
    De Baets, Greet
    Langenberg, Tobias
    Hipp, Mark S.
    Houben, Bert
    Claes, Filip
    Charbonneau, Sarah
    Blanco, Javier Delgado
    Plaisance, Stephane
    Ramkissoon, Shakti
    Ramkissoon, Lori
    Simons, Colinda
    van den Brandt, Piet
    Weijenberg, Matty
    Van England, Manon
    Lambrechts, Sandrina
    Amant, Frederic
    D'Hoore, Andre
    Ligon, Keith L.
    Sagaert, Xavier
    Schymkowitz, Joost
    Rousseau, Frederic
    JOURNAL OF PATHOLOGY, 2017, 242 (01) : 24 - 38
  • [8] Aspirin acetylates wild type and mutant p53 in colon cancer cells: identification of aspirin acetylated sites on recombinant p53
    Ai, Guoqiang
    Dachineni, Rakesh
    Kumar, D. Ramesh
    Marimuthu, Srinivasan
    Alfonso, Lloyd F.
    Bhat, G. Jayarama
    TUMOR BIOLOGY, 2016, 37 (05) : 6007 - 6016
  • [9] Mutant p53 rescue and modulation of p53 redox state
    Bykov, Vladimir J. N.
    Lambert, Jeremy M. R.
    Hainaut, Pierre
    Wiman, Klas G.
    CELL CYCLE, 2009, 8 (16) : 2509 - 2517
  • [10] Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein
    Vinyals, A
    Peinado, MA
    Gonzalez-Garrigues, M
    Monzó, M
    Bonfil, RD
    Fabra, A
    GENE THERAPY, 1999, 6 (01) : 22 - 33
12345